ANI Pharmaceuticals ANIP Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $923.71M+37.0% | $883.37M+43.8% | $826.88M+48.9% | $747.4M+38.7% | $674.07M+30.3% | ||
| $361.86M+32.0% | $341.31M+36.4% | $321.32M+43.9% | $291.01M+39.7% | $274.09M+42.0% | ||
| $561.85M+40.5% | $542.06M+48.8% | $505.56M+52.2% | $456.39M+38.1% | $399.98M+23.3% | ||
| 60.8%+1.5pp | 61.4%+2.1pp | 61.1%+1.4pp | 61.1%-0.3pp | 59.3%-3.4pp | ||
| $51.7M+15.8% | $51.66M+15.9% | $56.05M+48.3% | $53.87M+38.9% | $44.63M+14.8% | ||
| $314.87M+13.2% | $317.75M+27.3% | $304.67M+35.8% | $307.09M+63.9% | $278.14M+60.5% | ||
| $799.92M+19.8% | $772.27M+25.8% | $754.93M+38.8% | $732.21M+49.8% | $667.6M+45.1% | ||
| $123.79M— | $111.09M— | —— | —— | —— | ||
| 13.4%— | 12.6%— | —— | —— | —— | ||
| -$18.35M+0.8% | -$20.06M-14.0% | -$21.66M-25.0% | -$19.27M+10.0% | -$18.49M+22.5% | ||
| $1.09M+129% | $1.93M+148% | -$294K+89.1% | -$1.98M-929% | -$3.8M-2,322% | ||
| $116.03M+521% | $95.79M+531% | $50.55M+774% | -$14.75M-142% | -$27.56M-164% | ||
| $23.88M+467% | $17.45M+573% | $9.98M— | -$4.54M— | -$6.51M— | ||
| $92.15M+538% | $78.34M+523% | $40.57M+672% | -$10.21M-138% | -$21.05M-159% | ||
| 10%+13.1pp | 8.9%+11.9pp | 4.9%+6.2pp | -1.4%-6.4pp | -3.1%-10.0pp | ||
| $3.94+410% | $3.35+394% | $1.63+386% | -$0.77-167% | -$1.27-180% | ||
| $213.23M+218% | $202.51M+283% | $147.95M+105% | $84.31M-23.3% | $67M-42.8% | ||
| 23.1%+13.1pp | 22.9%+14.3pp | 17.9%+4.9pp | 11.3%-9.1pp | 9.9%-12.7pp | ||
| $123.79M+1,486% | $111.09M+850% | $56.55M+384% | -$210K-100% | -$8.93M-116% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is ANI Pharmaceuticals's revenue?
- ANI Pharmaceuticals (ANIP) generated $923.7M in revenue over the trailing twelve months, up 37.0% year over year.
- Is ANI Pharmaceuticals profitable?
- ANI Pharmaceuticals reported $92.1M in net income over the trailing twelve months, a 10.0% net margin.
- What are ANI Pharmaceuticals's profit margins?
- Gross margin is 60.8% and operating margin is 13.4%, with a 10.0% net margin.
- What is ANI Pharmaceuticals's earnings per share?
- ANI Pharmaceuticals's diluted EPS over the trailing twelve months is $3.94.
- Where does ANI Pharmaceuticals's income statement data come from?
- Every line is extracted from ANI Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
